Amarantus Bioscience Holdings, Inc. (OTCBB:AMBS) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

Shares of Amarantus Bioscience Holdings (AMBS) traded up 52.778% during mid-day trading on Friday, hitting $0.055. 736,893 shares of the stock were exchanged. The company has a 50-day moving average of $0.03 and a 200 day moving average of $0.04. Amarantus Bioscience Holdings has a one year low of $0.01 and a one year high of $0.09. The stock’s market cap is $3.75 million.

WARNING: “Amarantus Bioscience Holdings, Inc. (AMBS) Upgraded to “Sell” by ValuEngine” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/09/amarantus-bioscience-holdings-inc-ambs-upgraded-to-sell-by-valuengine.html.

Amarantus Bioscience Holdings Company Profile

Amarantus BioScience Holdings, Inc, a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amarantus Bioscience Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarantus Bioscience Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.